Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors

dc.contributor.authorArias, Fabio
dc.contributor.authorFranco-Montalban, Francisco
dc.contributor.authorRomero, Miguel
dc.contributor.authorDora Carrion, M.
dc.contributor.authorEncarnacion Camacho, M.
dc.contributor.authoraffiliation[Arias, Fabio] Univ Granada, Fac Farm, Dept Quim Farmaceut & Organ, Granada, Spain
dc.contributor.authoraffiliation[Franco-Montalban, Francisco] Univ Granada, Fac Farm, Dept Quim Farmaceut & Organ, Granada, Spain
dc.contributor.authoraffiliation[Dora Carrion, M.] Univ Granada, Fac Farm, Dept Quim Farmaceut & Organ, Granada, Spain
dc.contributor.authoraffiliation[Encarnacion Camacho, M.] Univ Granada, Fac Farm, Dept Quim Farmaceut & Organ, Granada, Spain
dc.contributor.authoraffiliation[Romero, Miguel] Univ Granada, Fac Farm, Dept Farmacol, Granada, Spain
dc.contributor.authoraffiliation[Romero, Miguel] Ibs GRANADA, Inst Invest Biosanitaria Granada, Granada, Spain
dc.contributor.authoraffiliation[Romero, Miguel] Univ Granada, Sch Pharm, Dept Pharmacol, Granada 18071, Spain
dc.contributor.authoraffiliation[Romero, Miguel] Univ Granada, Ctr Biomed Res CIBM, Granada 18071, Spain
dc.contributor.authoraffiliation[Romero, Miguel] Ciber Enfermedades Cardiovasc CIBERCV, Madrid, Spain
dc.contributor.funderComision Interministerial de Ciencia y Tecnologia, Ministerio de Economia y competitividad (MINECO)
dc.contributor.funderEuropean Union
dc.contributor.funderMinisterio de Economia y Competitividad, Instituto de Salud Carlos III (CIBER-CV)
dc.date.accessioned2025-01-07T16:47:02Z
dc.date.available2025-01-07T16:47:02Z
dc.date.issued2021-07-01
dc.description.abstractIn search of new Nitric Oxide Synthase (NOS) inhibitor agents, two isosteric series of derivatives with an imidamide scaffold (one of them with a hydroxyl group and the other with a carbonyl one) were synthesized and evaluated on inducible (iNOS) and neuronal (nNOS) isoforms. These compounds have been designed by combining a kynurenamine framework with an amidine moiety in order to improve selectivity for the inducible isoform. In general, the in vitro inhibitory assays exhibited better inhibition values on the iNOS isoform, being the N-(3-(2-amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimidamide 4i the most active inhibitor with the highest iNOS selectivity, without inhibiting eNOS. Docking studies on the two most active compounds suggest a different binding mode on both isozymes, supporting the experimentally observed selectivity towards the inducible isoform. Physicochemical in silico studies suggest that these compounds possess good drug-likeness properties.
dc.identifier.doi10.1016/j.bmc.2021.116294
dc.identifier.essn1464-3391
dc.identifier.issn0968-0896
dc.identifier.pmid34218000
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.bmc.2021.116294
dc.identifier.urihttps://hdl.handle.net/10668/27996
dc.identifier.wosID738750800010
dc.journal.titleBioorganic & medicinal chemistry
dc.journal.titleabbreviationBioorg. med. chem.
dc.language.isoen
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.publisherPergamon-elsevier science ltd
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDrug design
dc.subjectInhibitors
dc.subjectImidamides
dc.subjectNitric Oxide Synthase
dc.subjectSynthesis
dc.subjectBiological evaluation
dc.subjectInflammation
dc.subjectExpression
dc.subjectThiourea
dc.subjectAgonists
dc.subjectTarget
dc.subjectUrea
dc.subjectEnos
dc.titleSynthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number44
dc.wostypeArticle

Files